How big is the North America Glaucoma Therapeutics Market?

The North America Glaucoma Therapeutics Market is valued at US$ 2,634.52 Million in 2023, it is projected to reach US$ 3,421.64 Million by 2031.

What is the CAGR for North America Glaucoma Therapeutics Market by (2023 - 2031)?

As per our report North America Glaucoma Therapeutics Market, the market size is valued at US$ 2,634.52 Million in 2023, projecting it to reach US$ 3,421.64 Million by 2031. This translates to a CAGR of approximately 3.3% during the forecast period.

What segments are covered in this report?

The North America Glaucoma Therapeutics Market report typically cover these key segments- 药物类别（β受体阻滞剂、α肾上腺素能激动剂、前列腺素类似物、碳酸酐酶抑制剂、复方药物）适应症（开角型青光眼、闭角型青光眼）分销渠道（医院药房、零售药房、网上药房）

What is the historic period, base year, and forecast period taken for North America Glaucoma Therapeutics Market?

The historic period, base year, and forecast period can vary slightly depending on the specific market research report. However, for the North America Glaucoma Therapeutics Market report: 2025-2031 2023 2021-2023

Who are the major players in North America Glaucoma Therapeutics Market?

The North America Glaucoma Therapeutics Market is populated by several key players, each contributing to its growth and innovation. Some of the major players include: Alcon AG ; AbbVie Inc ; Bausch & Lomb Inc ; Fera Pharmaceuticals, LLC ; Viatris Inc ; Novartis AG ; Sun Pharmaceutical Industries Ltd ; Teva Pharmaceuticals Industries Ltd ; Thea Pharma Inc ; Santen Pharmaceutical Co., Ltd

Who should buy this report?

The North America Glaucoma Therapeutics Market report is valuable for diverse stakeholders, including: Investors: Provides insights for investment decisions pertaining to market growth, companies, or industry insights. Helps assess market attractiveness and potential returns. Industry Players: Offers competitive intelligence, market sizing, and trend analysis to inform strategic planning, product development, and sales strategies. Suppliers and Manufacturers: Helps understand market demand for components, materials, and services related to concerned industry. Researchers and Consultants: Provides data and analysis for academic research, consulting projects, and market studies. Financial Institutions: Helps assess risks and opportunities associated with financing or investing in the concerned market. Essentially, anyone involved in or considering involvement in the North America Glaucoma Therapeutics Market value chain can benefit from the information contained in a comprehensive market report.

北美青光眼治疗市场（主要地区、市场参与者、规模和份额）预测至 2031 年

2023年，北美青光眼治疗市场规模为26.3452亿美元，预计到2031年将达到34.2164亿美元；预计2023年至2031年的复合年增长率为3.3%。

青光眼发病率不断上升，推动北美青光眼治疗市场发展

青光眼是一种因视神经受损引起的眼部疾病，最终可能导致完全失明。青光眼患者可能会逐渐经历神经组织的损失，如果不及时治疗，会导致视力受损或失明。全球范围内，青光眼病例正在显著增加。根据青光眼研究基金会的数据，到 2040 年，全球预计将有 2200 万人因青光眼失明。此外，根据世界卫生组织的数据，青光眼是全球失明的主要原因，影响超过 6000 万人，导致约 450 万人失明。根据 2021 年 1 月发表在《视觉与眼科研究协会 (ARVO) 杂志》上的一篇文章的估计，到 2030 年、2040 年和 2050 年底，墨西哥患青光眼的人数将分别达到 250 万、300 万和 340 万。随着全球人口中青光眼病例的增加，对青光眼治疗的需求也在增加。旨在治疗这种疾病的医疗和外科手术侧重于降低眼压 (IOP)。前列腺素类似物是广泛推荐的药物之一，可通过促进眼部引流来有效降低眼压。这些产品由于疗效显著且不良反应有限，已成为青光眼治疗的主流。

北美青光眼治疗市场概览

根据人口参考局 2019 年的数据，到 2060 年，美国 65 岁及以上人口的数量预计将从 2018 年的 5200 万（占总人口的 16%）翻一番增加到近 9500 万（占总人口的 23%）。美国眼科学会 2019 年进行的一项研究表明，到 2050 年，美国估计将有近 732 万 70-75 岁人群患原发性开角型青光眼 (POAG)。因此，美国青光眼治疗市场的增长主要是由于眼部疾病患病率不断上升，尤其是在老年人口中。美国占北美青光眼治疗市场的最大份额。

市场参与者采用的各种有机和无机增长战略也为美国青光眼治疗市场的发展做出了显著贡献。下面提到了其中一些增长战略。

2023 年 10 月，Stuart Therapeutics 和 Glaukos 签署了 Stuart Therapeutics 的 ST-113 候选药物许可协议，该药物旨在保护青光眼的神经。2022 年 8 月，爱尔康收购了 Aerie Pharmaceuticals, Inc. 此次交易证实了爱尔康对眼科制药领域的承诺，预计爱尔康将通过增加更广泛的制药研发能力来增强其现有的商业专业知识，从而最大限度地提高其多元化产品组合的价值。北美青光眼治疗市场收入及预测至 2031 年（百万美元）

北美青光眼治疗市场细分

北美青光眼治疗市场分为药物类别、适应症、分销渠道和国家。

根据药物类别，北美青光眼治疗市场分为β受体阻滞剂、α肾上腺素能激动剂、前列腺素类似物、碳酸酐酶抑制剂、复方药物等。前列腺素类似物在2023年占据最大市场份额。

就适应症而言，北美青光眼治疗市场分为开角型青光眼、闭角型青光眼等。开角型青光眼在2023年占据最大市场份额。

按分销渠道，北美青光眼治疗市场分为医院药房、零售药房和网上药房。2023年，医院药房占据最大市场份额。

按国家/地区，北美青光眼治疗市场分为美国、加拿大和墨西哥。 2023 年，美国占据了北美青光眼治疗市场的主导地位。

Alcon AG、AbbVie Inc、Bausch & Lomb Inc、Fera Pharmaceuticals, LLC、Viatris Inc、Novartis AG、Sun Pharmaceutical Industries Ltd、Teva Pharmaceuticals Industries Ltd、Thea Pharma Inc 和 Santen Pharmaceutical Co., Ltd. 是北美青光眼治疗市场的主要公司。

North America Glaucoma Therapeutics Strategic Insights

Strategic insights for North America Glaucoma Therapeutics involve closely monitoring industry trends, consumer behaviours, and competitor actions to identify opportunities for growth. By leveraging data analytics, businesses can anticipate market shifts and make informed decisions that align with evolving customer needs. Understanding these dynamics helps companies adjust their strategies proactively, enhance customer engagement, and strengthen their competitive edge. Building strong relationships with stakeholders and staying agile in response to changes ensures long-term success in any market.

strategic-framework/north-america-glaucoma-therapeutics-market-strategic-framework.webp

Get more information on this report

North America Glaucoma Therapeutics Report Scope

Report Attribute	Details
Market size in 2023	US$ 2,634.52 Million
Market Size by 2031	US$ 3,421.64 Million
Global CAGR (2023 - 2031)	3.3%
Historical Data	2025-2031
Forecast period	2021-2023
Segments Covered	By 药物类别（β受体阻滞剂、α肾上腺素能激动剂、前列腺素类似物、碳酸酐酶抑制剂、复方药物） By 适应症（开角型青光眼、闭角型青光眼） By 分销渠道（医院药房、零售药房、网上药房）
Regions and Countries Covered	北美（美国、加拿大、墨西哥）北美（美国、加拿大、墨西哥）
Market leaders and key company profiles	Alcon AG AbbVie Inc Bausch & Lomb Inc Fera Pharmaceuticals, LLC Viatris Inc Novartis AG Sun Pharmaceutical Industries Ltd Teva Pharmaceuticals Industries Ltd Thea Pharma Inc Santen Pharmaceutical Co., Ltd

Get more information on this report

North America Glaucoma Therapeutics Regional Insights

The regional scope of North America Glaucoma Therapeutics refers to the geographical area in which a business operates and competes. Understanding regional nuances, such as local consumer preferences, economic conditions, and regulatory environments, is crucial for tailoring strategies to specific markets. Businesses can expand their reach by identifying underserved regions or adapting their offerings to meet regional demands. A clear regional focus allows for more effective resource allocation, targeted marketing, and better positioning against local competitors, ultimately driving growth in those specific areas.